pimobendan has been researched along with Arrhythmias, Cardiac in 9 studies
pimobendan: produces arterial & venous dilatation in dogs; structure given in first source
Arrhythmias, Cardiac: Any disturbances of the normal rhythmic beating of the heart or MYOCARDIAL CONTRACTION. Cardiac arrhythmias can be classified by the abnormalities in HEART RATE, disorders of electrical impulse generation, or impulse conduction.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To determine if pimobendan, a phosphodiesterase III inhibitor and calcium sensitizer with positive survival benefits, has an effect on incidence of arrhythmias compared to placebo in small breed dogs with congestive heart failure (CHF) due to myxomatous mitral valve degeneration (MMVD)." | 9.20 | Effect of pimobendan on the incidence of arrhythmias in small breed dogs with myxomatous mitral valve degeneration. ( Griffiths, LG; Kass, PH; Lake-Bakaar, GA; Singh, MK, 2015) |
| "The long-term beneficial effects of pimobendan in the treatment of chronic heart failure (CHF) have not been established, so the present trial compared pimobendan (1." | 9.10 | Effects of pimobendan on adverse cardiac events and physical activities in patients with mild to moderate chronic heart failure: the effects of pimobendan on chronic heart failure study (EPOCH study). ( , 2002) |
| "In 25 patients whose chronic congestive heart failure (CHF) had recently worsened to New York Heart Association class IV, pimobendan (5 to 20 mg/day) was added to maximum conventional therapy consisting of digoxin, diuretics, angiotensin-converting enzyme inhibitors, coumadin derivatives to prevent thromboembolic complications, and amiodarone to suppress serious ventricular rhythm disturbances." | 9.07 | Intractable heart failure despite angiotensin-converting enzyme inhibitors, digoxin, and diuretics: long-term effectiveness of add-on therapy with pimobendan. ( Hagemeijer, F, 1991) |
| " To assess the effects of phosphodiesterase type 3 and phosphodiesterase type 5 inhibitors on cardiac function and left ventricular myocardial fibrosis in catecholamine-induced myocardial injury, sildenafil and pimobendan were administered to male Wistar rats 24 hours after isoproterenol injection." | 7.91 | Contrasting Effects of Inhibition of Phosphodiesterase 3 and 5 on Cardiac Function and Interstitial Fibrosis in Rats With Isoproterenol-Induced Cardiac Dysfunction. ( Nakata, TM; Shimada, K; Suzuki, K; Tanaka, R; Uemura, A, 2019) |
| "The effects of milrinone and pimobendan upon the initiation of programmed ventricular stimulation-induced ventricular tachycardia (VT) and the incidence of lethal ischemic ventricular arrhythmias were assessed in conscious dogs with recent anterior myocardial infarctions." | 7.67 | Effects of the positive inotropic agents milrinone and pimobendan on the development of lethal ischemic arrhythmias in conscious dogs with recent myocardial infarction. ( Driscoll, EM; Frye, JW; Kitzen, JM; Lucchesi, BR; Lynch, JJ; Uprichard, AC, 1989) |
| "To determine if pimobendan, a phosphodiesterase III inhibitor and calcium sensitizer with positive survival benefits, has an effect on incidence of arrhythmias compared to placebo in small breed dogs with congestive heart failure (CHF) due to myxomatous mitral valve degeneration (MMVD)." | 5.20 | Effect of pimobendan on the incidence of arrhythmias in small breed dogs with myxomatous mitral valve degeneration. ( Griffiths, LG; Kass, PH; Lake-Bakaar, GA; Singh, MK, 2015) |
| "The long-term beneficial effects of pimobendan in the treatment of chronic heart failure (CHF) have not been established, so the present trial compared pimobendan (1." | 5.10 | Effects of pimobendan on adverse cardiac events and physical activities in patients with mild to moderate chronic heart failure: the effects of pimobendan on chronic heart failure study (EPOCH study). ( , 2002) |
| "In 25 patients whose chronic congestive heart failure (CHF) had recently worsened to New York Heart Association class IV, pimobendan (5 to 20 mg/day) was added to maximum conventional therapy consisting of digoxin, diuretics, angiotensin-converting enzyme inhibitors, coumadin derivatives to prevent thromboembolic complications, and amiodarone to suppress serious ventricular rhythm disturbances." | 5.07 | Intractable heart failure despite angiotensin-converting enzyme inhibitors, digoxin, and diuretics: long-term effectiveness of add-on therapy with pimobendan. ( Hagemeijer, F, 1991) |
| " To assess the effects of phosphodiesterase type 3 and phosphodiesterase type 5 inhibitors on cardiac function and left ventricular myocardial fibrosis in catecholamine-induced myocardial injury, sildenafil and pimobendan were administered to male Wistar rats 24 hours after isoproterenol injection." | 3.91 | Contrasting Effects of Inhibition of Phosphodiesterase 3 and 5 on Cardiac Function and Interstitial Fibrosis in Rats With Isoproterenol-Induced Cardiac Dysfunction. ( Nakata, TM; Shimada, K; Suzuki, K; Tanaka, R; Uemura, A, 2019) |
| "The effects of milrinone and pimobendan upon the initiation of programmed ventricular stimulation-induced ventricular tachycardia (VT) and the incidence of lethal ischemic ventricular arrhythmias were assessed in conscious dogs with recent anterior myocardial infarctions." | 3.67 | Effects of the positive inotropic agents milrinone and pimobendan on the development of lethal ischemic arrhythmias in conscious dogs with recent myocardial infarction. ( Driscoll, EM; Frye, JW; Kitzen, JM; Lucchesi, BR; Lynch, JJ; Uprichard, AC, 1989) |
| " Classic inotropic agents (beta-adrenergic agonists and phosphodiesterase III inhibitors) can provide short-term hemodynamic benefits, but their long-term use has been correlated with poor survival rates." | 2.43 | Calcium sensitizer agents: a new class of inotropic agents in the treatment of decompensated heart failure. ( Kaplinsky, EJ; Perrone, SV, 2005) |
| "Pretreatment with rolipram decreased the duration of ventricular tachycardia without any change in the incidences of dysrhythmias or the mortality rate." | 1.32 | Effects of rolipram, pimobendan and zaprinast on ischaemia-induced dysrhythmias and on ventricular cyclic nucleotide content in the anaesthetized rat. ( Aleixandre, F; Carceles, MD; Fuente, T; Laorden, ML; López-Vidal, J, 2003) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (11.11) | 18.7374 |
| 1990's | 1 (11.11) | 18.2507 |
| 2000's | 3 (33.33) | 29.6817 |
| 2010's | 4 (44.44) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Hillyer, S | 1 |
| Hezzell, M | 1 |
| Place, E | 1 |
| Nakata, TM | 1 |
| Suzuki, K | 1 |
| Uemura, A | 1 |
| Shimada, K | 1 |
| Tanaka, R | 1 |
| Lake-Bakaar, GA | 1 |
| Singh, MK | 1 |
| Kass, PH | 1 |
| Griffiths, LG | 1 |
| Carceles, MD | 1 |
| Aleixandre, F | 1 |
| Fuente, T | 1 |
| López-Vidal, J | 1 |
| Laorden, ML | 1 |
| Perrone, SV | 1 |
| Kaplinsky, EJ | 1 |
| Hagemeijer, F | 1 |
| Lynch, JJ | 1 |
| Uprichard, AC | 1 |
| Frye, JW | 1 |
| Driscoll, EM | 1 |
| Kitzen, JM | 1 |
| Lucchesi, BR | 1 |
2 reviews available for pimobendan and Arrhythmias, Cardiac
| Article | Year |
|---|---|
Is treatment with pimobendan associated with an increased risk of arrhythmias in dogs with heart disease?
Topics: Animals; Arrhythmias, Cardiac; Dog Diseases; Dogs; Heart Diseases; Pyridazines; Vasodilator Agents | 2018 |
Calcium sensitizer agents: a new class of inotropic agents in the treatment of decompensated heart failure.
Topics: Arrhythmias, Cardiac; Cardiotonic Agents; Heart Failure; Humans; Hydrazones; Pyridazines; Simendan | 2005 |
3 trials available for pimobendan and Arrhythmias, Cardiac
| Article | Year |
|---|---|
Effect of pimobendan on the incidence of arrhythmias in small breed dogs with myxomatous mitral valve degeneration.
Topics: Animals; Arrhythmias, Cardiac; Breeding; Cardiotonic Agents; Dog Diseases; Dogs; Double-Blind Method | 2015 |
Effects of pimobendan on adverse cardiac events and physical activities in patients with mild to moderate chronic heart failure: the effects of pimobendan on chronic heart failure study (EPOCH study).
Topics: Activities of Daily Living; Adult; Aged; Aged, 80 and over; Arrhythmias, Cardiac; Cardiotonic Agents | 2002 |
Intractable heart failure despite angiotensin-converting enzyme inhibitors, digoxin, and diuretics: long-term effectiveness of add-on therapy with pimobendan.
Topics: Aged; Amiodarone; Angiotensin-Converting Enzyme Inhibitors; Arrhythmias, Cardiac; Digoxin; Diuretics | 1991 |
4 other studies available for pimobendan and Arrhythmias, Cardiac
| Article | Year |
|---|---|
Clarification.
Topics: Animals; Arrhythmias, Cardiac; Dogs; Heart Diseases; Pyridazines | 2018 |
Contrasting Effects of Inhibition of Phosphodiesterase 3 and 5 on Cardiac Function and Interstitial Fibrosis in Rats With Isoproterenol-Induced Cardiac Dysfunction.
Topics: Animals; Arrhythmias, Cardiac; Collagen Type I; Collagen Type III; Disease Models, Animal; Fibrosis; | 2019 |
Effects of rolipram, pimobendan and zaprinast on ischaemia-induced dysrhythmias and on ventricular cyclic nucleotide content in the anaesthetized rat.
Topics: 3',5'-Cyclic-AMP Phosphodiesterases; 3',5'-Cyclic-GMP Phosphodiesterases; Anesthesia; Animals; Arrhy | 2003 |
Effects of the positive inotropic agents milrinone and pimobendan on the development of lethal ischemic arrhythmias in conscious dogs with recent myocardial infarction.
Topics: Animals; Arrhythmias, Cardiac; Cardiotonic Agents; Coronary Vessels; Dogs; Electric Stimulation; Ele | 1989 |